tetano
Editor, Senior Moderator
Viruses
. 2021 Jul 15;13(7):1371.
doi: 10.3390/v13071371.
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
Thomas Phelan[SUP] 1 [/SUP], Jean Dunne[SUP] 2 [/SUP], Niall Conlon[SUP] 2 3 [/SUP], Clíona Ní Cheallaigh[SUP] 1 4 [/SUP], W Mark Abbott[SUP] 5 [/SUP], Raquel Faba-Rodriguez[SUP] 5 [/SUP], Fatima Amanat[SUP] 6 [/SUP], Florian Krammer[SUP] 6 [/SUP], Mark A Little[SUP] 7 [/SUP], Gerry Hughes[SUP] 1 8 [/SUP], Colm Bergin[SUP] 1 4 [/SUP], Colm Kerr[SUP] 1 4 [/SUP], Sudharshana Sundaresan[SUP] 1 [/SUP], Aideen Long[SUP] 1 [/SUP], William McCormack[SUP] 1 [/SUP], Gareth Brady[SUP] 1 7 [/SUP]
Affiliations
Abstract
Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (n = 91) and pre-COVID-19 control sera (n = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed.
Keywords: SARS-CoV-2; antibody; enzyme-linked immunosorbent assay; neutralization; pseudovirus infection model; serology.
. 2021 Jul 15;13(7):1371.
doi: 10.3390/v13071371.
Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
Thomas Phelan[SUP] 1 [/SUP], Jean Dunne[SUP] 2 [/SUP], Niall Conlon[SUP] 2 3 [/SUP], Clíona Ní Cheallaigh[SUP] 1 4 [/SUP], W Mark Abbott[SUP] 5 [/SUP], Raquel Faba-Rodriguez[SUP] 5 [/SUP], Fatima Amanat[SUP] 6 [/SUP], Florian Krammer[SUP] 6 [/SUP], Mark A Little[SUP] 7 [/SUP], Gerry Hughes[SUP] 1 8 [/SUP], Colm Bergin[SUP] 1 4 [/SUP], Colm Kerr[SUP] 1 4 [/SUP], Sudharshana Sundaresan[SUP] 1 [/SUP], Aideen Long[SUP] 1 [/SUP], William McCormack[SUP] 1 [/SUP], Gareth Brady[SUP] 1 7 [/SUP]
Affiliations
- PMID: 34372581
- DOI: 10.3390/v13071371
Abstract
Serological assays have been widely employed during the coronavirus disease 2019 (COVID-19) pandemic to measure antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to track seroconversion in populations. However, currently available assays do not allow determination of neutralization capacity within the assay protocol. Furthermore, commercial serology assays have a high buy-in cost that is inaccessible for many research groups. We have replicated the serological enzyme-linked immunosorbent assay for the detection of SARS-CoV-2 antibody isotypes, developed at the Icahn School of Medicine at Mount Sinai, New York. Additionally, we have modified the protocol to include a neutralization assay with only a minor modification to this protocol. We used this assay to screen local COVID-19 patient sera (n = 91) and pre-COVID-19 control sera (n = 103), and obtained approximate parity with approved commercial anti-nucleoprotein-based assays with these sera. Furthermore, data from our neutralization assay closely aligns with that generated using a spike-based pseudovirus infection model when a subset of patient sera was analyzed.
Keywords: SARS-CoV-2; antibody; enzyme-linked immunosorbent assay; neutralization; pseudovirus infection model; serology.